Cycling peptides: what the research suggests about breaks
Why some peptide protocols build in off periods — and what the research does and does not show about receptor sensitivity.
TL;DR
- Receptor desensitization — the gradual reduction in a receptor's response to repeated stimulation — is a well-documented pharmacological phenomenon relevant to peptide use.
- Human studies of continuous GHRH infusion are mixed: one found a partial loss of pituitary response within hours, another found the response preserved after 14 days.
- The prescribing physician sets any on/off schedule — the right structure depends on the compound and individual.
What it is
Cycling in pharmacology refers to intentional periods of use followed by intentional breaks. It is not a practice unique to peptides — receptor-based therapies of many kinds use cycling to preserve receptor sensitivity over time. With peptides that act on G protein-coupled receptors (GPCRs), like GHRH receptors, there is a specific mechanism that makes cycling clinically relevant: tachyphylaxis.
Tachyphylaxis is a rapid decrease in response to a drug after repeated administration. The underlying biology typically involves receptor downregulation — the cell reduces the number of available receptors at its surface in response to sustained stimulation — or post-receptor adaptation in the signaling cascade downstream.
How it works
When a peptide like sermorelin repeatedly stimulates the GHRH receptor in the pituitary, the pituitary's somatotroph cells adjust. Some protocols add rest periods on the idea that, without breaks, the GH response to the same dose may diminish.
The human data are mixed. In healthy men, a 6-hour GHRH infusion left the pituitary partly less responsive to a further GHRH dose, although its overall reserve of growth hormone was not reduced (Vance et al., J Clin Endocrinol Metab, 1986). In a later study, 14 days of continuous GHRH infusion in healthy men did not blunt the response: GH pulses and the response to a further GHRH dose were preserved (Vance et al., J Clin Endocrinol Metab, 1989).
Who asks about it
People who are several months into a peptide protocol, or who are designing their first one, often ask about cycling. The question usually takes the form of: "Do I really need the off days, or is that just precautionary?" The short answer is that the underlying mechanism is real — receptor desensitization is not a hypothetical — and the off periods are meant to let sensitivity recover.
What the research says
These studies used continuous intravenous GHRH, not the injections used in peptide protocols, so they do not show whether off days help.
For ghrelin receptor agonists, similar receptor adaptation dynamics have been observed in preclinical models, though the time course and magnitude differ from GHRH receptor tachyphylaxis. Published protocols in the clinical literature and in functional medicine practice structure these breaks in different ways, and the optimal structure has not been established in a randomized controlled trial for compounded peptide protocols.
What to know before considering it
Cycling should be managed by a physician, not improvised. A physician familiar with peptide pharmacology will design the on/off structure based on the specific compounds in your protocol, your lab trends over time, and your subjective response. Self-adjusting protocol timing based on online forums — rather than clinical oversight — removes the physician feedback loop that cycling depends on.
The Halftime POV
The cycling question is a good indicator of whether someone is approaching peptides seriously or impulsively. A protocol that includes structured rest periods is one designed with the underlying biology in mind. The body's receptor systems evolved for pulsatile signaling — episodic, rhythmic, with gaps. Good protocol design respects that architecture rather than trying to override it with continuous stimulation.
Related reading:
FAQ
Q: Why do peptide protocols include off days? A: Receptor desensitization — the gradual reduction in a receptor's response to repeated stimulation — is a well-documented pharmacological phenomenon. For GHRH, the human data are mixed. In one study, a few hours of continuous infusion made the pituitary partly less responsive to a further dose; in another, the response was preserved after 14 days of continuous infusion.
Q: What is peptide cycling? A: Cycling refers to intentional periods of peptide use followed by structured breaks. The prescribing physician sets the schedule. The goal is to preserve receptor sensitivity over time by allowing receptor populations to recover between stimulation periods.
Q: Is cycling required for all peptides? A: Not uniformly. The cycling rationale is most often discussed for GHRH-receptor-targeting peptides like sermorelin, though human data on GHRH tachyphylaxis are mixed. The appropriate cycling structure depends on the specific compound, dosing, and the individual's response — determined by a physician, not by general guidelines.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Vance ML, et al. Dual effects of growth hormone (GH)-releasing hormone infusion in normal men: somatotroph desensitization and increase in releasable GH. Journal of Clinical Endocrinology & Metabolism, 1986.
- Vance ML, et al. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. Journal of Clinical Endocrinology & Metabolism, 1989.
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Why do peptide protocols include off days?
Receptor desensitization — the gradual reduction in a receptor's response to repeated stimulation — is a well-documented pharmacological phenomenon. For GHRH, the human data are mixed. In one study, a few hours of continuous infusion made the pituitary partly less responsive to a further dose; in another, the response was preserved after 14 days of continuous infusion.
What is peptide cycling?
Cycling refers to intentional periods of peptide use followed by structured breaks. The prescribing physician sets the schedule. The goal is to preserve receptor sensitivity over time by allowing receptor populations to recover between stimulation periods.
Is cycling required for all peptides?
Not uniformly. The cycling rationale is most often discussed for GHRH-receptor-targeting peptides like sermorelin, though human data on GHRH tachyphylaxis are mixed. The appropriate cycling structure depends on the specific compound, dosing, and the individual's response — determined by a physician, not by general guidelines.
Keep reading
Buying peptides online? There is a route with labs first and a licensed physician.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.